CN116601713A - 用于抗her2抗体-药物缀合物疗法的评分方法 - Google Patents
用于抗her2抗体-药物缀合物疗法的评分方法 Download PDFInfo
- Publication number
- CN116601713A CN116601713A CN202180077294.6A CN202180077294A CN116601713A CN 116601713 A CN116601713 A CN 116601713A CN 202180077294 A CN202180077294 A CN 202180077294A CN 116601713 A CN116601713 A CN 116601713A
- Authority
- CN
- China
- Prior art keywords
- cancer
- adc
- cell
- amino acid
- seq
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- G—PHYSICS
- G06—COMPUTING OR CALCULATING; COUNTING
- G06V—IMAGE OR VIDEO RECOGNITION OR UNDERSTANDING
- G06V20/00—Scenes; Scene-specific elements
- G06V20/60—Type of objects
- G06V20/69—Microscopic objects, e.g. biological cells or cellular parts
- G06V20/698—Matching; Classification
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/5758—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites
- G01N33/5759—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites involving compounds localised on the membrane of tumour or cancer cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
- A61K47/68037—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a camptothecin [CPT] or derivatives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/32—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
-
- G—PHYSICS
- G06—COMPUTING OR CALCULATING; COUNTING
- G06F—ELECTRIC DIGITAL DATA PROCESSING
- G06F18/00—Pattern recognition
- G06F18/20—Analysing
- G06F18/24—Classification techniques
- G06F18/241—Classification techniques relating to the classification model, e.g. parametric or non-parametric approaches
- G06F18/2413—Classification techniques relating to the classification model, e.g. parametric or non-parametric approaches based on distances to training or reference patterns
- G06F18/24133—Distances to prototypes
-
- G—PHYSICS
- G06—COMPUTING OR CALCULATING; COUNTING
- G06V—IMAGE OR VIDEO RECOGNITION OR UNDERSTANDING
- G06V10/00—Arrangements for image or video recognition or understanding
- G06V10/40—Extraction of image or video features
- G06V10/44—Local feature extraction by analysis of parts of the pattern, e.g. by detecting edges, contours, loops, corners, strokes or intersections; Connectivity analysis, e.g. of connected components
- G06V10/443—Local feature extraction by analysis of parts of the pattern, e.g. by detecting edges, contours, loops, corners, strokes or intersections; Connectivity analysis, e.g. of connected components by matching or filtering
- G06V10/449—Biologically inspired filters, e.g. difference of Gaussians [DoG] or Gabor filters
- G06V10/451—Biologically inspired filters, e.g. difference of Gaussians [DoG] or Gabor filters with interaction between the filter responses, e.g. cortical complex cells
- G06V10/454—Integrating the filters into a hierarchical structure, e.g. convolutional neural networks [CNN]
-
- G—PHYSICS
- G06—COMPUTING OR CALCULATING; COUNTING
- G06V—IMAGE OR VIDEO RECOGNITION OR UNDERSTANDING
- G06V10/00—Arrangements for image or video recognition or understanding
- G06V10/70—Arrangements for image or video recognition or understanding using pattern recognition or machine learning
- G06V10/74—Image or video pattern matching; Proximity measures in feature spaces
- G06V10/75—Organisation of the matching processes, e.g. simultaneous or sequential comparisons of image or video features; Coarse-fine approaches, e.g. multi-scale approaches; using context analysis; Selection of dictionaries
- G06V10/751—Comparing pixel values or logical combinations thereof, or feature values having positional relevance, e.g. template matching
-
- G—PHYSICS
- G06—COMPUTING OR CALCULATING; COUNTING
- G06V—IMAGE OR VIDEO RECOGNITION OR UNDERSTANDING
- G06V20/00—Scenes; Scene-specific elements
- G06V20/60—Type of objects
- G06V20/69—Microscopic objects, e.g. biological cells or cellular parts
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
-
- G—PHYSICS
- G06—COMPUTING OR CALCULATING; COUNTING
- G06V—IMAGE OR VIDEO RECOGNITION OR UNDERSTANDING
- G06V2201/00—Indexing scheme relating to image or video recognition or understanding
- G06V2201/03—Recognition of patterns in medical or anatomical images
Landscapes
- Engineering & Computer Science (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Theoretical Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Physics & Mathematics (AREA)
- General Physics & Mathematics (AREA)
- Chemical & Material Sciences (AREA)
- Molecular Biology (AREA)
- Computer Vision & Pattern Recognition (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Biomedical Technology (AREA)
- Multimedia (AREA)
- Evolutionary Computation (AREA)
- Artificial Intelligence (AREA)
- Medicinal Chemistry (AREA)
- Data Mining & Analysis (AREA)
- Organic Chemistry (AREA)
- Biochemistry (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Evolutionary Biology (AREA)
- Bioinformatics & Computational Biology (AREA)
- Biodiversity & Conservation Biology (AREA)
- Software Systems (AREA)
- Medical Informatics (AREA)
- Databases & Information Systems (AREA)
- Computing Systems (AREA)
- General Engineering & Computer Science (AREA)
- Oncology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Epidemiology (AREA)
- Cell Biology (AREA)
- Animal Behavior & Ethology (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063077604P | 2020-09-12 | 2020-09-12 | |
| US63/077604 | 2020-09-12 | ||
| PCT/IB2021/058273 WO2022054009A2 (en) | 2020-09-12 | 2021-09-11 | A scoring method for an anti-her2 antibody-drug conjugate therapy |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN116601713A true CN116601713A (zh) | 2023-08-15 |
Family
ID=77801755
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202180077294.6A Pending CN116601713A (zh) | 2020-09-12 | 2021-09-11 | 用于抗her2抗体-药物缀合物疗法的评分方法 |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20240426826A1 (https=) |
| EP (1) | EP4211598B1 (https=) |
| JP (1) | JP2023545359A (https=) |
| KR (1) | KR20230066094A (https=) |
| CN (1) | CN116601713A (https=) |
| AU (2) | AU2021340002B9 (https=) |
| CA (1) | CA3195062A1 (https=) |
| ES (1) | ES3064041T3 (https=) |
| IL (1) | IL301265A (https=) |
| WO (1) | WO2022054009A2 (https=) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2025103192A1 (zh) * | 2023-11-16 | 2025-05-22 | 上海齐鲁制药研究中心有限公司 | 一种氘代喜树碱化合物及其制备和应用 |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20240037740A1 (en) * | 2022-07-28 | 2024-02-01 | Applied Materials, Inc. | Method and system for automatic ihc marker-her2 score |
| EP4623936A1 (en) * | 2022-11-22 | 2025-10-01 | Keymed Biosciences (Chengdu) Co., Ltd. | Fused ring compound, conjugate thereof and use thereof |
| WO2025162211A1 (zh) * | 2024-01-29 | 2025-08-07 | 正大天晴药业集团股份有限公司 | 抗her2抗体药物偶联物治疗胃癌的用途 |
Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN107743586A (zh) * | 2015-06-03 | 2018-02-27 | 百时美施贵宝公司 | 用于癌症诊断的抗gitr抗体 |
| US20190026422A1 (en) * | 2015-02-16 | 2019-01-24 | Lonza Ltd | Method and apparatus for designing proteins |
| US20190392580A1 (en) * | 2018-06-26 | 2019-12-26 | Definiens Ag | Deep Learning Method For Tumor Cell Scoring On Cancer Biopsies |
| CN110651188A (zh) * | 2017-03-03 | 2020-01-03 | 特雷斯生物公司 | 基于群体的免疫原性肽鉴定平台 |
| WO2020023213A1 (en) * | 2018-07-27 | 2020-01-30 | Ventana Medical Systems, Inc. | Systems for automated in situ hybridization analysis |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL162181A (en) | 1988-12-28 | 2006-04-10 | Pdl Biopharma Inc | A method of producing humanized immunoglubulin, and polynucleotides encoding the same |
| EP1400536A1 (en) | 1991-06-14 | 2004-03-24 | Genentech Inc. | Method for making humanized antibodies |
| DK1071700T3 (da) | 1998-04-20 | 2010-06-07 | Glycart Biotechnology Ag | Glykosylerings-modifikation af antistoffer til forbedring af antistofafhængig cellulær cytotoksicitet |
| CA2953239A1 (en) | 2000-10-06 | 2002-04-18 | Kyowa Hakko Kirin Co., Ltd. | Antibody composition-producing cell |
| EP2854851A4 (en) * | 2012-06-01 | 2016-03-30 | Momenta Pharmaceuticals Inc | Methods related to trastuzumab |
| IL310627B2 (en) * | 2014-01-31 | 2026-04-01 | Daiichi Sankyo Co Ltd | Anti-HER2 antibody-drug conjugates, compositions containing them and uses thereof |
| EP3659110A1 (en) * | 2017-07-24 | 2020-06-03 | Ventana Medical Systems, Inc. | Methods and systems for evaluation of immune cell infiltrate in tumor samples |
| EP3721373B1 (en) * | 2017-12-07 | 2025-03-05 | Ventana Medical Systems, Inc. | Deep-learning systems and methods for joint cell and region classification in biological images |
| EP3797296B1 (en) * | 2018-05-21 | 2024-09-04 | Genentech, Inc. | Her2 heterogeneity as a biomarker in cancer |
| WO2022162164A1 (en) * | 2021-01-29 | 2022-08-04 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods of assessing the risk of developing progressive multifocal leukoencephalopathy in patients treated with vla-4 antagonists |
-
2021
- 2021-09-11 CN CN202180077294.6A patent/CN116601713A/zh active Pending
- 2021-09-11 WO PCT/IB2021/058273 patent/WO2022054009A2/en not_active Ceased
- 2021-09-11 IL IL301265A patent/IL301265A/en unknown
- 2021-09-11 EP EP21772839.3A patent/EP4211598B1/en active Active
- 2021-09-11 KR KR1020237012303A patent/KR20230066094A/ko active Pending
- 2021-09-11 AU AU2021340002A patent/AU2021340002B9/en active Active
- 2021-09-11 CA CA3195062A patent/CA3195062A1/en active Pending
- 2021-09-11 JP JP2023515569A patent/JP2023545359A/ja active Pending
- 2021-09-11 ES ES21772839T patent/ES3064041T3/es active Active
- 2021-09-11 US US18/025,896 patent/US20240426826A1/en active Pending
-
2024
- 2024-09-17 AU AU2024219803A patent/AU2024219803A1/en active Pending
Patent Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20190026422A1 (en) * | 2015-02-16 | 2019-01-24 | Lonza Ltd | Method and apparatus for designing proteins |
| CN107743586A (zh) * | 2015-06-03 | 2018-02-27 | 百时美施贵宝公司 | 用于癌症诊断的抗gitr抗体 |
| CN110651188A (zh) * | 2017-03-03 | 2020-01-03 | 特雷斯生物公司 | 基于群体的免疫原性肽鉴定平台 |
| US20190392580A1 (en) * | 2018-06-26 | 2019-12-26 | Definiens Ag | Deep Learning Method For Tumor Cell Scoring On Cancer Biopsies |
| WO2020023213A1 (en) * | 2018-07-27 | 2020-01-30 | Ventana Medical Systems, Inc. | Systems for automated in situ hybridization analysis |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2025103192A1 (zh) * | 2023-11-16 | 2025-05-22 | 上海齐鲁制药研究中心有限公司 | 一种氘代喜树碱化合物及其制备和应用 |
Also Published As
| Publication number | Publication date |
|---|---|
| IL301265A (en) | 2023-05-01 |
| JP2023545359A (ja) | 2023-10-30 |
| AU2021340002B2 (en) | 2024-06-20 |
| EP4211598B1 (en) | 2026-01-07 |
| CA3195062A1 (en) | 2022-03-17 |
| AU2021340002A1 (en) | 2023-05-25 |
| US20240426826A1 (en) | 2024-12-26 |
| WO2022054009A2 (en) | 2022-03-17 |
| ES3064041T3 (en) | 2026-04-22 |
| EP4211598A2 (en) | 2023-07-19 |
| AU2024219803A1 (en) | 2024-10-10 |
| WO2022054009A3 (en) | 2022-04-21 |
| KR20230066094A (ko) | 2023-05-12 |
| AU2021340002B9 (en) | 2024-09-12 |
| AU2021340002A9 (en) | 2024-08-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2021340002B2 (en) | A scoring method for an anti-her2 antibody-drug conjugate therapy | |
| JP4799863B2 (ja) | 癌制御方法 | |
| US20230176060A1 (en) | Tumour biomarkers for immunotherapy | |
| JP2025509564A (ja) | 抗trop2抗体-薬物コンジュゲート治療のためのスコアリング方法 | |
| RU2706967C2 (ru) | Антитело к igf-1r и его применение для диагностики рака | |
| JP7829563B2 (ja) | 抗b7h4抗体薬物コンジュゲート療法のためのスコア化方法 | |
| RU2706959C2 (ru) | Антитело к igf-1r и его применение для диагностики рака | |
| JP2023542301A5 (https=) | ||
| WO2026052764A1 (en) | A scoring method for an anti-trop2 antibody drug conjugate therapy | |
| US20250352645A1 (en) | Biomarkers and methods for treating nsclc | |
| US11046779B2 (en) | Antibody specifically binding to PAUF protein and use thereof | |
| HK40025609A (en) | Antibody specifically binding to pauf protein and use thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination |